Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis

BACKGROUND: A comparison between atezolizumab plus bevacizumab (ATEZO/BEVA) and lenvatinib (LEN) for the treatment of hepatocellular carcinoma (HCC) remains unclear. OBJECTIVE: This study aimed to compare the therapeutic effects and safety of ATEZO/BEVA and LEN as first-line therapies for HCC. PATIE...

Descripción completa

Detalles Bibliográficos
Autores principales: Niizeki, Takashi, Tokunaga, Takayuki, Takami, Yuko, Wada, Yoshiyuki, Harada, Masaru, Shibata, Michihiko, Nakao, Kazuhiko, Sasaki, Ryu, Hirai, Fumihito, Shakado, Satoshi, Yoshizumi, Tomoharu, Itoh, Shinji, Yatsuhashi, Hiroshi, Bekki, Shigemune, Ido, Akio, Mawatari, Seiichi, Honda, Koichi, Sugimoto, Rie, Senju, Takeshi, Takahashi, Hirokazu, Kuwashiro, Takuya, Maeshiro, Tatsuji, Nakamuta, Makoto, Aratake, Yoshifusa, Yamashita, Tsutomu, Otsuka, Yuichiro, Matsumoto, Shuichi, Sohda, Tetsuro, Shimose, Shigeo, Murotani, Kenta, Tanaka, Yasuhito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684293/
https://www.ncbi.nlm.nih.gov/pubmed/36272060
http://dx.doi.org/10.1007/s11523-022-00921-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684293/
https://www.ncbi.nlm.nih.gov/pubmed/36272060
http://dx.doi.org/10.1007/s11523-022-00921-x

Ejemplares similares